Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre Prospective Phase II Single Arm Trial Evaluating the Benefit of Therapy With Lenalidomide (Revlimid®) in Relapsed or Refractory Primary-cutaneous Large B-cell Lymphoma (Leg-type) After First Line Treatment by Chemotherapy Plus Rituximab for the French Study Group of Cutaneous Lymphoma (GFELC)

NCT01556035 is registered in ClinicalTrials.gov with University Hospital, Bordeaux as lead sponsor.

NCT NCT01556035
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01556035 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre Prospective Phase II Single Arm Trial Evaluating the Benefit of Therapy With Lenalidomide (Revlimid®) in Relapsed or Refractory Primary-cutaneous Large B-cell Lymphoma (Leg-type) After First Line Treatment by Chemotherapy Plus Rituximab for the French Study Group of Cutaneous Lymphoma (GFELC)
Lead sponsor
University Hospital, Bordeaux
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2012
Completion date
August 31, 2015
Enrollment
19 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

refractory primary-cutaneous large b-cell lymphoma (leg-type)